Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results

Bulletin Express

08/13

Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.

The notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.

The current board comprises: • Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading • Non-executive Director – Dr. Lu An • Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai

No additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1162000898"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162000898\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162000898?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162000898","market":"us","top_or_hot":-1,"title":"Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results","media":"Bulletin Express","content":"<p>Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.</p>\n<p>The notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.</p>\n<p>The current board comprises:  \n• Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading  \n• Non-executive Director – Dr. Lu An  \n• Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai</p>\n<p>No additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-08-13 19:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.</p>\n<p>The notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.</p>\n<p>The current board comprises:  \n• Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading  \n• Non-executive Director – Dr. Lu An  \n• Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai</p>\n<p>No additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09637","symbol_name":"禮邦醫藥-B","start_time":0,"source_url":"","article_id":"1162000898","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162000898","pubTimestamp":1786621402,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09637":"礼邦医药-B"},"translate_title":"Alebund Pharmaceuticals 定于 2026 年 8 月 26 日召开董事会会议批准 26 年上半年中期业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09637":1},"content_text":"Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.\nThe notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.\nThe current board comprises:  \n• Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading  \n• Non-executive Director – Dr. Lu An  \n• Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai\nNo additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}